Cargando…

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine

This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereaf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobashi, Yurie, Shimazu, Yuzo, Kawamura, Takeshi, Nishikawa, Yoshitaka, Omata, Fumiya, Kaneko, Yudai, Kodama, Tatsuhiko, Tsubokura, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Fukushima Society of Medical Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071351/
https://www.ncbi.nlm.nih.gov/pubmed/35228456
http://dx.doi.org/10.5387/fms.2021-28
_version_ 1784700828451340288
author Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_facet Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_sort Kobashi, Yurie
collection PubMed
description This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test).
format Online
Article
Text
id pubmed-9071351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Fukushima Society of Medical Science
record_format MEDLINE/PubMed
spelling pubmed-90713512022-05-17 Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu Fukushima J Med Sci Brief Report This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test). The Fukushima Society of Medical Science 2022-02-25 2022 /pmc/articles/PMC9071351/ /pubmed/35228456 http://dx.doi.org/10.5387/fms.2021-28 Text en © 2022 The Fukushima Society of Medical Science https://creativecommons.org/licenses/by-nc-sa/4.0/This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. https://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Brief Report
Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title_full Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title_fullStr Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title_full_unstemmed Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title_short Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
title_sort peak igg antibody titers against sars-cov-2 spike protein following immunization with the pfizer/biontech bnt162b2 vaccine
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071351/
https://www.ncbi.nlm.nih.gov/pubmed/35228456
http://dx.doi.org/10.5387/fms.2021-28
work_keys_str_mv AT kobashiyurie peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT shimazuyuzo peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT kawamuratakeshi peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT nishikawayoshitaka peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT omatafumiya peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT kanekoyudai peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT kodamatatsuhiko peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine
AT tsubokuramasaharu peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine